StockData
Biogen Inc. logo

Biogen Inc. (BIIB) stock

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)

Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –

Biogen EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Biogen's EV/EBITDA was 16.9× on Nov 11, 2026, against 7.8× a year earlier. Over the last 5 years it ranged from 5.8× to 18.3×, with a median of 9.5×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202616.9×+9.5
2025Dec 31, 20257.5×+0.1
2024Dec 31, 20247.4×−7.9
2023Dec 29, 202315.3×+6.7
2022Dec 30, 20228.5×−5.6
2021Dec 31, 202114.2×+8.7
2020Dec 31, 20205.4×−1.9
2019Dec 31, 20197.3×−1.3
2018Dec 31, 20188.6×−3.0
2017Dec 29, 201711.6×+1.7
2016Dec 30, 20169.9×−2.5
2015Dec 31, 201512.4×−6.7
2014Dec 31, 201419.1×−4.8
2013Dec 31, 201323.9×+7.1
2012Dec 31, 201216.8×−0.4
2011Dec 30, 201117.2×+5.7
2010Dec 31, 201011.5×+2.5
2009Dec 31, 20099.0×–

More Biogen figures

See a number that looks wrong?